Leora Horn

Leora Horn has investigated pembrolizumab and other checkpoint inhibitors in thymic tumors, noting the important and paradoxical challenge of severe immune-related adverse events — particularly myocarditis, myasthenic crisis, and other autoimmune toxicities — in thymoma patients treated with PD-1 blockade. Her work has characterized the safety signals and response rates in thymic carcinoma vs. thymoma and contributed to rational guidance for immunotherapy use in these tumors.